Due to the aggressive clinical behavior of pancreatic adenocarcinomas, this tumor type may represent an ideal cancer type for clinical trials studying new drugs targeting MTAP-deficient cancer cells. The gene discussed is MTAP; the disease is pancreatic adenocarcinoma.